Page 150 - Haematologica Vol. 109 - July 2024

ARTICLE - Patterns of lower risk MDS progresion
A.G. Jain et al.
intermediate-1-risk myelodysplastic syndromes. Ann Intern
Med. 2020;173(7):595-596.
12. Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower
IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179(1):83-97.
13. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376-3382.
14. Bernard E, Tuechler H, Greenberg Peter L, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evidence. 2022;1(7):EVIDoa2200008.
15. Aguirre LE, Al Ali N, Ball S, et al. Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes. Blood. 2022;140(Suppl 1):1125-1127.
16. Komrokji RS, George TI, Erba HP, et al. Treatment patterns and outcomes of patients with lower-risk myelodysplastic syndromes in the connect ® myeloid disease registry. Blood. 2021;138(Suppl 1):3686.
17. Mądry K, Lis K, Fenaux P, et al. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS registry. Br J Haematol. 2023;200(4):451-461.
18. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low- risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579-585.
19. Jain AG, Elmariah H. BMT for Myelodysplastic syndrome: when and where and how. Front Oncol. 2021;11:771614.
20. de Witte T, Bowen D, Robin M, et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129(13):1753-1762.
21. Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96(3):441-449.
22. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011;29(16):2240-2246.
23. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-121.
24. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-847.
Haematologica | 109 July 2024
2164